Last reviewed · How we verify
JYB1904
JYB1904 is a small molecule targeting the S1P1 receptor.
JYB1904 is a small molecule targeting the S1P1 receptor. Used for Relapsing multiple sclerosis.
At a glance
| Generic name | JYB1904 |
|---|---|
| Also known as | JYB1904 Injection |
| Sponsor | Jemincare |
| Drug class | S1P1 receptor antagonist |
| Target | S1P1 |
| Modality | Small molecule |
| Therapeutic area | Autoimmune diseases |
| Phase | Phase 3 |
Mechanism of action
S1P1 receptor antagonists like JYB1904 are being investigated for their potential to treat various autoimmune diseases by inhibiting the S1P1 receptor, which plays a crucial role in lymphocyte trafficking and immune response.
Approved indications
- Relapsing multiple sclerosis
Common side effects
- Nausea
- Headache
- Diarrhea
Key clinical trials
- Trial of JYB1904 Injection in Patients With Perennial Allergic Rhinitis (PHASE2)
- Phase 2b Study of RPT904 as Monotherapy in Participants With IgE-Mediated Food Allergy (PHASE2)
- Trial of JYB1904 Injection in Adult Patients With Chronic Spontaneous Urticaria. (PHASE3)
- Trial of JYB1904 in Patients With Allergic Asthma (PHASE2)
- Trial of JYB1904 in Chronic Spontaneous Urticaria. (PHASE2)
- Study of JYB1904 (an Anti-immunoglobulin E Antibody) in Healthy Chinese Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- JYB1904 CI brief — competitive landscape report
- JYB1904 updates RSS · CI watch RSS
- Jemincare portfolio CI